Mallinckrodt PLC reached a settlement with the US Department of Justice to resolve a portion of the government's claims that it paid kickbacks to boost prescriptions of its H.P. Acthar Gel (repository corticotropin injection). But it is still in litigation over its arrangement with a charitable foundation, which could lead to a much higher payout.
The DOJ announced on 4 September that Mallinckrodt agreed to pay $15.4m to resolve claims that its Questcor Pharmaceuticals Inc. subsidiary paid illegal kickbacks to doctors, in the form of lavish dinners and entertainment, to induce them to prescribe Acthar